세계의 인플루엔자 진단 시장 규모 : 제품별, 최종사용자별, 검사 유형별, 지역별, 범위 및 예측

Influenza Diagnostics Market Size And Forecast

Influenza Diagnostics Market size was valued at USD 0.84 Billion in 2024 and is projected to reach USD 1.56 Billion by 2031 , growing at a CAGR of 9.00% from 2024 to 2031. Influenza, commonly known as the flu, is an infection caused by the influenza virus. A variety of traditional and molecular diagnostic technologies are used to identify and diagnose influenza. Reverse transcription-polymerase chain reaction and real-time molecular testing allows the detection of influenza genetic material. Continued advances in rapid influenza diagnostic testing have made this method effective for diagnosis due to its rapid results and ease of sample collection. Factors such as the increasing prevalence of influenza, increasing awareness of early detection using specific diagnostic tests, and a shift in focus from centralized laboratories to decentralized point-of-care testing are expected to drive the growth of the global influenza diagnostics market.

Additionally, due to the increasing prevalence of chronic diseases, the growing geriatric population, increasing government initiatives to monitor influenza, and the development of technologically advanced diagnostic tests for influenza, the demand for influenza diagnostics is likely to increase.

Emerging technologically advanced influenza diagnostic tests, including integration of point-of-care technology and influenza testing, are expected to facilitate the surveillance process in the geriatric population. In addition, point-of-care technology is expected to increase influenza testing in rural areas of the Asia-Pacific region, where access to health care is limited.

However, the cost of test and equipment development may hamper the market growth. Raw material availability and accessibility constraints increase the total cost of the product. The burden of high production costs is passed on to end users at high prices.

Global Influenza Diagnostics Market Dynamics

The key market dynamics that are shaping the global influenza diagnostics market include:

Key Market Drivers

Escalating Burden of Influenza:

Global seasonal influenza outbreaks cause significant sickness, hospitalizations, and deaths, emphasizing the need for rapid and precise diagnostic techniques. These tools are critical for making treatment decisions and carrying out effective management measures.

Increased Healthcare Awareness:

As the public becomes more aware of influenza and its repercussions, there is a greater demand for quick and simple diagnostic testing. This development represents a proactive attitude to health management, with people seeking easily accessible diagnostic solutions.

Advancements in Technology:

Novel technologies including as fast molecular assays, point-of-care tests, and multiplex assays are transforming influenza diagnostics. These advancements improve speed, accuracy, and the ability to identify many influenza strains at the same time, hence increasing diagnostic capabilities.

Emphasis on Early Detection and Treatment:

Early detection and treatment are crucial for early treatment and preventing complications from influenza. Rapid diagnostic tests allow for early intervention with antiviral drugs, which improves patient outcomes and reduces healthcare costs.

Expanding Geriatric Population

: As the world population ages, the elderly are especially vulnerable to influenza-related problems. This demographic transition highlights the importance of reliable and conveniently accessible diagnostic testing adapted to the demands of older persons.

Biothreat Preparedness:

Influenza viruses have the potential to cause pandemics, hence rapid and accurate diagnostic technologies are required for biothreat preparedness and response operations. Effective diagnostics are critical for limiting outbreaks and minimizing their damage.

Government Initiatives and Reimbursement Policies:

Several governments are launching public health initiatives to promote influenza vaccination and diagnosis. Furthermore, favorable payment rules for influenza diagnostic tests play an important role in increasing accessibility and encouraging widespread usage of these critical instruments.

Key Challenges:

Variability in Test Sensitivity and Specificity:

Inconsistencies in test performance, especially with quick testing, can lead to incorrect discrimination between influenza and other respiratory infections, resulting in misdiagnosis and poor treatment recommendations.

High Cost of Advanced Tests:

Advanced technologies such as molecular assays provide greater precision but come at a higher cost, limiting access, particularly in resource-constrained regions with restricted healthcare budgets.

Lack of Standardization:

The prevalence of several influenza diagnostic tests with differing performance characteristics complicates interpreting and comparing results across tests, causing uncertainty for healthcare practitioners and impeding effective patient treatment decisions.

Limited Availability in Remote Areas:

Access to advanced diagnostic tests is limited in distant or low-income areas, delaying diagnosis and treatment, especially for vulnerable groups that face barriers to accessing healthcare facilities with advanced testing capabilities.

Limited Skilled Personnel:

Certain modern influenza diagnostic tests necessitate specific training and skills to operate and interpret correctly. Even when these tests are available, a lack of competent workers in certain places prevents them from being used effectively.

Reimbursement Issues:

Inadequate reimbursement regulations for influenza diagnostics may prevent healthcare providers from adopting newer technologies, limiting overall market growth and the availability of improved tests.

False Positives and Negatives:

Despite improvements, some tests continue to provide false positive or negative results, resulting in wasteful treatments, resource waste, and patient worry, compromising the effectiveness and cost-efficiency of testing methodologies.

Evolving Viral Strains:

Influenza viruses are constantly changing, demanding ongoing updates and changes to diagnostic procedures in order to remain successful. The introduction of novel virus strains may result in increased expenditures and hurdles for diagnostic manufacturers in maintaining accurate and trustworthy diagnostic systems.

Key Trends:

Adoption of Rapid Diagnostic Tests:

Rapid influenza diagnostic tests (RIDTs) are becoming increasingly popular because to their convenience, speed, and ease of use, allowing for swift treatment decisions at the point of care.

Emergence of Multiplex Assays:

Multiplex assays are becoming popular because they may detect numerous respiratory infections, such as influenza viruses and RSV, in a single test, increasing efficiency and eliminating the need for multiple tests.

Focus on Point-of-Care Testing (POCT):

The industry is shifting toward developing point-of-care testing (POCT) solutions for influenza diagnostics, which will provide portable and user-friendly options for a variety of locations, including clinics, pharmacies, and homes.

Integration with Telehealth Platforms:

Influenza diagnostic tests are rapidly being connected with telehealth platforms, allowing for remote diagnosis and consultation, hence enhancing healthcare access, particularly in underprivileged areas.

Technological Advances in Molecular Diagnostics:

As technology advances, more sensitive and specific molecular assays for influenza diagnosis are being developed, allowing for differentiation between different influenza strains and aiding in targeted treatment strategies and vaccine development.

Integration of Artificial Intelligence:

Artificial intelligence (AI) algorithms are being integrated into influenza diagnostics to improve accuracy, identify new strains, and anticipate epidemics by using diagnostic test data analysis.

Growing Emphasis on Home-Based Testing:

The COVID-19 pandemic has increased demand for home-based diagnostic tests, and similar trends are projected for influenza diagnostics, as advances in user-friendly self-testing kits become more widely available.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Influenza Diagnostics Market Regional Analysis

Here is a more detailed regional analysis of the global influenza diagnostics market:

North America

North America is significantly dominating the influenza diagnostics market and is expected to continue its growth throughout the forecast period, owing to several variables.

North America has a well-developed healthcare infrastructure that includes cutting-edge medical facilities, advanced laboratories, and a qualified workforce. This infrastructure facilitates the effective diagnosis and management of influenza patients, which contributes to the region's market leadership.

The region is home to leading pharmaceutical businesses, diagnostic manufacturers, and research organizations focused on improving influenza diagnostics. Ongoing research and development activities are aimed at inventing new diagnostic technologies, improving test accuracy, and increasing testing accessibility, thereby cementing North America's position as a dominating market participant.

North America routinely devotes a high portion of its GDP to healthcare spending, allowing for major investment in healthcare technologies such as influenza diagnostics. The availability of large financial resources encourages the use of modern diagnostic tests and promotes market expansion in the region.

Each year, North America suffers significant seasonal influenza outbreaks, which cause a significant illness burden and public health impact. The incidence of influenza increases the demand for speedy and accurate diagnostic tests to guide treatment decisions, implement control measures, and limit disease spread, supporting the region's dominant position in the influenza diagnostics market.

Many of the world's largest influenza diagnostic firms, including those that make fast tests, molecular assays, and point-of-care devices, have their headquarters or a significant presence in North America. These companies use the region's superior infrastructure, research capabilities, and regulatory framework to develop and deliver breakthrough diagnostic solutions, reinforcing North America's market leadership.

Asia Pacific

Asia Pacific is anticipated to be the fastest-growing region in the influenza diagnostics The Asia Pacific area is undergoing rapid economic expansion, which has coincided with advancements in healthcare infrastructure and access to medical services. Rising disposable incomes and government investments in healthcare drive up demand for diagnostic tests, especially those for influenza.

As Asia Pacific countries invest more in healthcare infrastructure and services, healthcare spending rises. This increasing investment promotes the use of innovative diagnostic technologies, hence driving growth in the influenza diagnostics market.

The Asia Pacific region's public is becoming more aware of infectious diseases, particularly influenza. Increased awareness generates more demand for diagnostic testing, particularly during influenza seasons, which contributes to market growth.

The Asia Pacific region has a vast and fast expanding population, especially in cities. Increased population density raises the risk of influenza transmission, driving up need for diagnostic tests to monitor and manage illness spread.

Countries in the Asia Pacific area are increasingly adopting innovative healthcare technologies, such as telemedicine platforms and point-of-care diagnostic devices. These technologies provide access to healthcare services and enable faster detection and treatment of influenza, resulting in market growth.

The COVID-19 pandemic has expedited the deployment of telehealth platforms throughout the Asia Pacific. The integration of influenza diagnostic tests with telehealth services allows for remote consultations and testing, increasing access to diagnostic services and driving market growth.

Global Influenza Diagnostics Market: Segmentation Analysis

The Global Influenza Diagnostics Market is segmented based on Product, End-User, Test Type, And Geography.

Influenza Diagnostics Market, By Product

• Test kits and reagents.
• Instruments
• Others

Based on Product, the market is segmented into test kits and reagents, instruments, and others. Test kits and reagents dominate the Influenza Diagnostics Market, accounting for almost 60% of the total market share. This is due to a variety of causes, including its widespread availability through pharmacies, clinics, and internet sellers, frequently without the requirement for a prescription. These test kits are popular because they are simple to use; many are developed for point-of-care settings and require little training to administer. Furthermore, their low cost in comparison to other instruments makes them affordable to those with a variety of budgets. Given the importance of early influenza detection, these kits meet a significant need by offering a quick and accessible testing alternative. Furthermore, their versatility enables them to serve both healthcare professionals and those seeking self-testing choices at home.

Influenza Diagnostics Market, By End-User

• Diagnostics laboratories
• Hospitals & Clinic
• Others

Based on End-users, the Global Influenza Diagnostics Market has been segmented into diagnostics laboratories, hospitals & clinics, and others. Hospitals and Clinics dominate the Influenza Diagnostics Market, owing to a number of important considerations. For starters, hospitals face a larger disease load, with a greater number of patients presenting with influenza-like symptoms, demanding frequent testing to ensure correct diagnosis and treatment decisions. Second, hospitals often have advanced testing capabilities, including access to a wide range of diagnostic tools and sophisticated apparatus, allowing for more precise and extensive testing procedures. Furthermore, hospitals have strong infrastructure and specialized people, such as dedicated laboratory facilities and trained experts who can successfully handle and interpret influenza diagnostic tests. Given the importance of prompt and correct diagnosis in patient treatment, hospitals prioritize diagnostic accuracy and efficiency. Furthermore, hospitals play an important role in public health surveillance by reporting influenza cases, relying on dependable diagnostic results to inform public health interventions and strategies.

Influenza Diagnostics Market, By Test Type

• Traditional Test
• Molecular Diagnostic Assay

Based on Test Type, the Global Influenza Diagnostics Market is classified into traditional tests and molecular diagnostic assay. While the Influenza Diagnostics Market is moving, traditional tests, such as Rapid Influenza Diagnostic Tests (RIDTs), continue to hold the majority share, accounting for around 66.7%. This is mostly due to various variables. First and foremost, traditional tests are less expensive than molecular assays, making them more accessible in a variety of healthcare settings. Furthermore, many traditional tests, particularly RIDTs, provide speedy results at the point of care, allowing for timely treatment options. Furthermore, their ease of use, with no administration training, makes them appropriate for widespread deployment in clinics and even self-testing. Given the high prevalence of influenza A and B, standard tests can detect the most common influenza strains, meeting a major amount of diagnostic needs. Moreover, the frequent use of traditional testing over a longer period has solidified their position in healthcare settings, contributing to their continued dominance in the market.

Influenza Diagnostics Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world

Based on Geography, the Global Influenza Diagnostics Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America is significantly dominating the influenza diagnostics market and is expected to continue its growth throughout the forecast period, owing to several variables. North America has a well-developed healthcare infrastructure that includes cutting-edge medical facilities, advanced laboratories, and a qualified workforce. This infrastructure facilitates the effective diagnosis and management of influenza patients, which contributes to the region's market leadership. The region is home to leading pharmaceutical businesses, diagnostic manufacturers, and research organizations focused on improving influenza diagnostics. Ongoing research and development activities are aimed at inventing new diagnostic technologies, improving test accuracy, and increasing testing accessibility, thereby cementing North America's position as a dominating market participant.

Key Players

• The "Global Influenza Diagnostics Market" study report will provide valuable insight emphasizing the global market. The major players in the market are
• Abbott Laboratories, F. Hoffmann-La Roche Ltd. (Roche Diagnostics), Danaher Corporation (Beckton Dickinson), Abbott Laboratories (Alere), Siemens Healthineers AG, Thermo Fisher Scientific Inc., Becton, Dickinson and Company (BD Diagnostics), Meril Diagnostics Pvt. Ltd., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., and QIAGEN.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• In May 2021, FDA approval has been received by Becton, Dickinson, and Company which is a medical technology company for the BD Veritor Plus System. The BD Veritor Plus System will play a vital role in detecting influenza A, influenza B, and SARS-CoV-2.
• In March 2021, Emergency Use Authorization (EUA) was received from FDA for a laboratory PCR assay that will be beneficial in detecting and differentiating SARS-COV-2, RSV flu A, and flu B in a single test. It is manufactured by Abbott Laboratories which is a leading medical device and health care company.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 MARKET DEFINITION
• 1.2 MARKET SEGMENTATION
• 1.3 RESEARCH TIMELINES
• 1.4 ASSUMPTIONS
• 1.5 LIMITATIONS

2 RESEARCH METHODOLOGY

• 2.1 DATA MINING
• 2.2 SECONDARY RESEARCH
• 2.3 PRIMARY RESEARCH
• 2.4 SUBJECT MATTER EXPERT ADVICE
• 2.5 QUALITY CHECK
• 2.6 FINAL REVIEW
• 2.7 DATA TRIANGULATION
• 2.8 BOTTOM-UP APPROACH
• 2.9 TOP-DOWN APPROACH
• 2.1 RESEARCH FLOW
• 2.11 DATA SOURCES

3 EXECUTIVE SUMMARY

• 3.1 GLOBAL INFLUENZA DIAGNOSTICS MARKET OVERVIEW
• 3.2 GLOBAL INFLUENZA DIAGNOSTICS ABSOLUTE MARKET OPPORTUNITY
• 3.3 GLOBAL INFLUENZA DIAGNOSTICS MARKET ATTRACTIVENESS, BY REGION
• 3.4 GLOBAL INFLUENZA DIAGNOSTICS MARKET ATTRACTIVENESS, BY PRODUCT
• 3.5 GLOBAL INFLUENZA DIAGNOSTICS MARKET ATTRACTIVENESS, BY END-USER
• 3.6 GLOBAL INFLUENZA DIAGNOSTICS MARKET ATTRACTIVENESS, BY TEST TYPE
• 3.7 GLOBAL INFLUENZA DIAGNOSTICS MARKET GEOGRAPHICAL ANALYSIS (CAGR %)
• 3.8 GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT (USD MILLION)
• 3.9 GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY END USER (USD MILLION)
• 3.1 GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE (USD MILLION)
• 3.11 FUTURE MARKET OPPORTUNITIES
• 3.12 GLOBAL MARKET SPLIT

4 MARKET OUTLOOK

• 4.1 GLOBAL INFLUENZA DIAGNOSTICS MARKET EVOLUTION
• 4.2 GLOBAL INFLUENZA DIAGNOSTICS MARKET OUTLOOK
• 4.3 MARKET DRIVERS
  • 4.3.1 GROWTH IN INFLUENZA RESEARCH FOR DIAGNOSTIC TECHNOLOGIES
  • 4.3.2 RISE IN PREVALENCE OF INFLUENZA
• 4.4 RESTRAINTS
  • 4.4.1 UNSKILLED PROFESSIONALS
  • 4.4.2 STRINGENT FDA REGULATIONS
• 4.5 OPPORTUNITIES
  • 4.5.1 ADVANCEMENTS IN GENOMIC AND PROTEOMIC TECHNOLOGIES
  • 4.5.2 INCREASE IN THE NUMBER OF RESEARCH AND DEVELOPMENT ACTIVITIES
• 4.6 IMPACT OF COVID-19 ON THE GLOBAL INFLUENZA DIAGNOSTICS MARKET
• 4.7 PORTER'S FIVE FORCES ANALYSIS
  • 4.7.1 BARGAINING POWER OF BUYERS
  • 4.7.2 BARGAINING POWER OF SUPPLIERS
  • 4.7.3 THREAT OF SUBSTITUTES
  • 4.7.4 THREAT FROM NEW ENTRANTS
  • 4.7.5 INTENSITY OF COMPETITIVE RIVALRY
• 4.8 VALUE CHAIN ANALYSIS
• 4.9 MACROECONOMIC ANALYSIS

5 MARKET, BY END-USER

• 5.1 OVERVIEW
• 5.1 DIAGNOSTIC LABORATORIES
• 5.2 HOSPITALS AND CLINICS
• 5.3 OTHERS

6 MARKET, BY PRODUCT

• 6.1 OVERVIEW
• 6.2 TEST KIT AND REAGENTS
• 6.3 INSTRUMENTS
• 6.4 OTHERS

7 MARKET, BY TEST TYPE

• 7.1 OVERVIEW
• 7.2 TRADITIONAL DIAGNOSTIC TEST
  • 7.2.1 RAPID INFLUENZA DIAGNOSTIC TEST (RIDT)
  • 7.2.2 VIRAL CULTURE
  • 7.2.3 DIRECT FLUORESCENT ANTIBODY (DFA) TEST
  • 7.2.4 SEROLOGICAL ASSAY
• 7.3 MOLECULAR DIAGNOSTIC ASSAY
  • 7.3.1 RT-PCR
  • 7.3.2 NUCLEIC ACID SEQUENCE-BASED AMPLIFICATION (NASBA) TEST
  • 7.3.3 LOOP-MEDIATED ISOTHERMAL AMPLIFICATION-BASED ASSAY (LAMP)
  • 7.3.4 SIMPLE AMPLIFICATION-BASED ASSAY (SAMBA)
  • 7.3.5 OTHER MOLECULAR DIAGNOSTIC ASSAYS

8 MARKET, BY GEOGRAPHY

• 8.1 OVERVIEW
• 8.2 NORTH AMERICA
  • 8.2.1 NORTH AMERICA MARKET SNAPSHOT
  • 8.2.2 U.S.
  • 8.2.3 CANADA
  • 8.2.4 MEXICO
• 8.3 EUROPE
  • 8.3.1 EUROPE MARKET SNAPSHOT
  • 8.3.2 GERMANY
  • 8.3.3 U.K.
  • 8.3.4 FRANCE
  • 8.3.5 ITALY
  • 8.3.6 SPAIN
  • 8.3.7 REST OF EUROPE
• 8.4 ASIA PACIFIC
  • 8.4.1 ASIA PACIFIC MARKET SNAPSHOT
  • 8.4.2 CHINA
  • 8.4.3 JAPAN
  • 8.4.4 INDIA
  • 8.4.5 REST OF ASIA PACIFIC
• 8.5 LATIN AMERICA
  • 8.5.1 LATIN AMERICA MARKET SNAPSHOT
  • 8.5.2 BRAZIL
  • 8.5.3 ARGENTINA
  • 8.5.4 REST OF LATIN AMERICA
• 8.6 MIDDLE EAST AND AFRICA
  • 8.6.1 MIDDLE EAST AND AFRICA MARKET SNAPSHOT
  • 8.6.2 UAE
  • 8.6.3 SAUDI ARABIA
  • 8.6.4 SOUTH AFRICA
  • 8.6.5 REST OF MIDDLE EAST AND AFRICA

9 COMPETITIVE LANDSCAPE

• 9.1 OVERVIEW
• 9.2 COMPETITIVE SCENARIO
• 9.3 COMPANY MARKET RANKING ANALYSIS
• 9.4 COMPANY REGIONAL FOOTPRINT
• 9.5 COMPANY INDUSTRY FOOTPRINT
• 9.6 ACE MATRIX
  • 9.6.1 ACTIVE
  • 9.6.2 CUTTING EDGE
  • 9.6.3 EMERGING
  • 9.6.4 INNOVATORS

10 COMPANY PROFILES

• 10.1 ABBOTT LABORATORIES
  • 10.1.1 COMPANY OVERVIEW
  • 10.1.2 COMPANY INSIGHTS
  • 10.1.3 SEGMENT BREAKDOWN
  • 10.1.4 PRODUCT BENCHMARKING
  • 10.1.5 KEY DEVELOPMENTS
  • 10.1.6 WINNING IMPERATIVES
  • 10.1.7 CURRENT FOCUS & STRATEGIES
  • 10.1.8 THREAT FROM COMPETITION
  • 10.1.9 SWOT ANALYSIS
• 10.2 THERMO FISHER SCIENTIFIC INC.
  • 10.2.1 COMPANY OVERVIEW
  • 10.2.2 COMPANY INSIGHTS
  • 10.2.3 SEGMENT BREAKDOWN
  • 10.2.4 PRODUCT BENCHMARKING
  • 10.2.5 KEY DEVELOPMENTS
  • 10.2.6 WINNING IMPERATIVES
  • 10.2.7 CURRENT FOCUS & STRATEGIES
  • 10.2.8 THREAT FROM COMPETITION
  • 10.2.9 SWOT ANALYSIS
• 10.3 DANAHER CORPORATION
  • 10.3.1 COMPANY OVERVIEW
  • 10.3.2 COMPANY INSIGHTS
  • 10.3.3 SEGMENT BREAKDOWN
  • 10.3.4 PRODUCT BENCHMARKING
  • 10.3.5 WINNING IMPERATIVES
  • 10.3.6 CURRENT FOCUS & STRATEGIES
  • 10.3.7 THREAT FROM COMPETITION
  • 10.3.8 SWOT ANALYSIS
• 10.4 SIEMENS HEALTHINEERS AG
  • 10.4.1 COMPANY OVERVIEW
  • 10.4.2 COMPANY INSIGHTS
  • 10.4.3 SEGMENT BREAKDOWN
  • 10.4.4 PRODUCT BENCHMARKING
  • 10.4.5 KEY DEVELOPMENTS
  • 10.4.6 WINNING IMPERATIVES
  • 10.4.7 CURRENT FOCUS & STRATEGIES
  • 10.4.8 THREAT FROM COMPETITION
  • 10.4.9 SWOT ANALYSIS
• 10.5 HOFFMANN-LA ROCHE AG
  • 10.5.1 COMPANY OVERVIEW
  • 10.5.2 COMPANY INSIGHTS
  • 10.5.3 SEGMENT BREAKDOWN
  • 10.5.4 PRODUCT BENCHMARKING
  • 10.5.5 KEY DEVELOPMENTS
  • 10.5.6 WINNING IMPERATIVES
  • 10.5.7 CURRENT FOCUS & STRATEGIES
  • 10.5.8 THREAT FROM COMPETITION
  • 10.5.9 SWOT ANALYSIS
• 10.6 BECTON, DICKINSON, AND COMPANY
  • 10.6.1 COMPANY OVERVIEW
  • 10.6.2 COMPANY INSIGHTS
  • 10.6.3 SEGMENT BREAKDOWN
  • 10.6.4 PRODUCT BENCHMARKING
  • 10.6.5 KEY DEVELOPMENTS
• 10.7 DIASORIN & LUMINEX CORPORATION
  • 10.7.1 COMPANY OVERVIEW
  • 10.7.2 COMPANY INSIGHTS
  • 10.7.3 SEGMENT BREAKDOWN
  • 10.7.4 PRODUCT BENCHMARKING
  • 10.7.5 KEY DEVELOPMENTS
  • 10.7.6 LUMINEX CORPORATION COMPANY OVERVIEW
  • 10.7.7 PRODUCT BENCHMARKING
• 10.8 QUIDEL CORPORATION
  • 10.8.1 COMPANY OVERVIEW
  • 10.8.2 COMPANY INSIGHTS
  • 10.8.3 SEGMENT BREAKDOWN
  • 10.8.4 PRODUCT BENCHMARKING
  • 10.8.5 KEY DEVELOPMENTS
• 10.9 CORIS BIOCONCEPT
  • 10.9.1 COMPANY OVERVIEW
  • 10.9.2 COMPANY INSIGHTS
  • 10.9.3 PRODUCT BENCHMARKING
• 10.1 ANALYTIK JENA AG (ENDRESS+HAUSER AG)
  • 10.10.1 COMPANY OVERVIEW
  • 10.10.2 COMPANY INSIGHTS
  • 10.10.3 SEGMENT BREAKDOWN
  • 10.10.4 PRODUCT BENCHMARKING
• 10.11 MERIDIAN BIOSCIENCE
  • 10.11.1 COMPANY OVERVIEW
  • 10.11.2 COMPANY INSIGHTS
  • 10.11.3 SEGMENT BREAKDOWN
  • 10.11.4 PRODUCT BENCHMARKING
• 10.12 SA SCIENTIFIC, LTD
  • 10.12.1 COMPANY OVERVIEW
  • 10.12.2 COMPANY INSIGHTS
  • 10.12.3 PRODUCT BENCHMARKING
• 10.13 SEKISUI DIAGNOSTIC
  • 10.13.1 COMPANY OVERVIEW
  • 10.13.2 COMPANY INSIGHTS
  • 10.13.3 PRODUCT BENCHMARKING
  • 10.13.4 KEY DEVELOPMENTS
• 10.14 HOLOGIC INC.
  • 10.14.1 COMPANY OVERVIEW
  • 10.14.2 COMPANY INSIGHTS
  • 10.14.3 SEGMENT BREAKDOWN
  • 10.14.4 PRODUCT BENCHMARKING
  • 10.14.5 KEY DEVELOPMENTS
• 10.15 3M
  • 10.15.1 COMPANY OVERVIEW
  • 10.15.2 COMPANY INSIGHTS
  • 10.15.3 SEGMENT BREAKDOWN
  • 10.15.4 PRODUCT BENCHMARKING
• 10.16 BIOMERIEUX SA
  • 10.16.1 COMPANY OVERVIEW
  • 10.16.2 COMPANY INSIGHTS
  • 10.16.3 SEGMENT BREAKDOWN
  • 10.16.4 PRODUCT BENCHMARKING
• 10.17 GENMARK DIAGNOSTICS INC.
  • 10.17.1 COMPANY OVERVIEW
  • 10.17.2 COMPANY INSIGHTS
  • 10.17.3 PRODUCT BENCHMARKING
• 10.18 ALTONA DIAGNOSTICS
  • 10.18.1 COMPANY OVERVIEW
  • 10.18.2 COMPANY INSIGHTS
  • 10.18.3 PRODUCT BENCHMARKING
  • 10.18.4 KEY DEVELOPMENT
• 10.19 ELITECH GROUP
  • 10.19.1 COMPANY OVERVIEW
  • 10.19.2 COMPANY INSIGHTS
  • 10.19.3 PRODUCT BENCHMARKING
• 10.2 MAST GROUP LTD
  • 10.20.1 COMPANY OVERVIEW
  • 10.20.2 COMPANY INSIGHTS
  • 10.20.3 PRODUCT BENCHMARKING
• 10.21 KONINKLIJKE PHILIPS N.V.
  • 10.21.1 COMPANY OVERVIEW
  • 10.21.2 COMPANY INSIGHTS
  • 10.21.3 SEGMENT BREAKDOWN
  • 10.21.4 PRODUCT BENCHMARKING
• 10.22 SYSMEX CORPORATION
  • 10.22.1 COMPANY OVERVIEW
  • 10.22.2 COMPANY INSIGHTS
  • 10.22.3 SEGMENT BREAKDOWN
  • 10.22.4 PRODUCT BENCHMARKING